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Introduction
Adenosine and its primary metabolite inosine are ubi-
quitous nucleosides that can be released in substantial
quantities from ischemic tissue and stimulated mast
cells (1–4). Adenosine acts through cell-surface adeno-
sine receptors to orchestrate numerous physiological
events in multiple tissues. Few physiological roles have
been ascribed to inosine, and only recently has it been
shown that inosine can participate in receptor-mediat-
ed signaling (5). To date, 4 adenosine receptors have
been identified, A1, A2A, A2B, and A3, each with unique
tissue distributions, ligand affinity, and signal trans-
duction mechanisms (6). A1 and A2A receptors are acti-
vated by submicromolar concentrations of adenosine,
whereas A2B and A3 receptors become activated only
when adenosine levels rise into the micromolar range.
Inosine has been shown to bind to A3 receptors in the
range of 10–50 µM (5). These differences in ligand affin-
ity have important physiological implications, as tissue
levels of adenosine and inosine are believed to increase
into the micromolar range during periods of inflam-
mation, hypoxia, or ischemia (1, 3, 4, 7). Hence, the A2B
and A3 receptors have become attractive pharmacologic
targets for modifying the inflammatory response.
Changes in microvascular permeability are crucial to
the development and perpetuation of the inflammato-
ry response. It has been recognized for many years that
adenosine can produce vasodilatation and increases in
capillary permeability in numerous vascular beds
(8–11). Although there is evidence that cAMP-coupled
A2 receptors on vascular smooth muscle are responsible
for adenosine-mediated vasodilatation (12), the precise
mechanism involved and the receptors mediating vas-
cular permeability changes are not as well established
(13–15). Furthermore, it is not clear whether adenosine
acts directly on endothelial cells, or if the observed
increase in vascular permeability is indirect, resulting
from mediator release by stimulated immune cells.
A number of lines of evidence suggest that adenosine
receptors are present on endothelial cells and that
direct activation of these receptors results in alteration
of endothelial permeability. Although the permeabili-
ty of in vitro monolayers of macrovascular aortic
endothelial cells decreases in response to adenosine,
microvascular endothelial cells demonstrate adeno-
sine-induced increases in permeability (16, 17). Several
whole-vessel preparations and in vivo studies in multi-
ple tissues have shown increases in microvascular per-
meability after exposure to adenosine; however, these
experiments are confounded by adenosine’s effects on
perivascular immune cells (9–11).
Mast cells are present in most tissues and are often
found in close proximity to blood vessels, including
capillaries and postcapillary venules (18–20). Upon
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stimulation, these cells release a number of mediators,
including leukotrienes, histamine, and serotonin, that
act directly on the vasculature to produce vasodilata-
tion, increased permeability, and subsequent plasma
protein extravasation into surrounding tissue (21). The
ability to release these vasoactive substances suggests
that the mast cell may play a key role in regulating
these physiological processes.
Modulation of mast-cell function by adenosine has
been extensively investigated. In vitro studies have
shown that adenosine can potentiate mediator release
from stimulated mast cells but cannot provoke medi-
ator release alone (22). However, a number of studies
suggest that adenosine can initiate mast-cell degran-
ulation in vivo in the absence of additional stimuli
(23, 24). Because adenosine fails to initiate degranu-
lation of mast cells in culture, it is not clear that this
in vivo response is mediated by binding of adenosine
to a particular receptor and, moreover, which of the
adenosine receptors found on mast cells is required
for this response.
Efforts to define the adenosine receptor responsible
for these effects on mast-cell degranulation has been
difficult owing to incomplete specificity of receptor
agonists and antagonists. Nevertheless, most studies
suggest that A2B and A3 receptors are predominantly
involved (24–32). The differential importance assigned
to these receptors in mast-cell degranulation may
reflect the fact that mast cells examined were from dif-
ferent species and tissues.
To further delineate the mechanisms by which
adenosine and its principal metabolite inosine mediate
proinflammatory effects on tissues, we examined the
vascular response to these nucleosides using 3 mutant
mouse lines; namely, mice lacking the A3 adenosine
receptor, mice lacking mast cells, and mice lacking a
functional high-affinity receptor for IgE. These animals
have enabled us both to define the mechanism by
which adenosine induces changes in cutaneous vascu-
lar permeability in vivo and to determine the receptor
through which adenosine and inosine exert these phys-
iological effects.
Methods
Animal welfare. The use of experimental animals was in
accordance with the Institutional Animal Care and Use
Committee guidelines of the University of North Car-
olina at Chapel Hill.
A3AR-deficient, FcεR1 β chain–deficient, and mast cell–defi-
cient mice. Gene targeting in murine embryonic stem
cells was used to generate mice deficient in the A3AR
and in the β chain of the FcεR1 high-affinity IgE recep-
tor as described previously (32, 33). Mast cell–deficient
mice (WBB6F1/J-W/WV) and their congenic normal litter
mates (WBB6F1/J-W/W+) were purchased from The Jack-
son Laboratory (Bar Harbor, Maine, USA). Experiments
were carried out with A3AR–/– mice of various ages, rang-
ing from 16 to 98 weeks old. Age-matched littermates
were used as A3AR+/+ controls in all experiments. Mast
cell–deficient mice and their controls ranged from 10 to
16 weeks old. FcεR1 β chain–deficient mice and their
controls ranged from 10 to 14 weeks old.
Isolation of bone marrow–derived mast cells. Bone mar-
row–derived mast cells (BMMCs) were isolated from
the femurs of 3- to 6-month-old mice and placed in cul-
ture for at least 4 weeks in the presence of murine IL-3
to select for pure populations of mast cells as described
previously (34). Culture media consisted of RPMI 1640
medium supplemented with 8% FCS, 8% murine IL-3
culture supplement (Collaborative Biomedical Prod-
ucts, Bedford, Massachusetts, USA), 20 mM HEPES, 4
mM L-glutamine, 0.08 U/mL penicillin, 0.08 U/mL
streptomycin, 800 µM nonessential amino acids, 800
µM sodium pyruvate, 0.04 mg/mL gentamicin, and 92
µM β-mercaptoethanol. Cell cultures were maintained
at a constant 37°C in a humidified chamber contain-
ing 5% CO2. Adherent cells (macrophages, monocytes)
were depleted from culture by transferring cells in sus-
pension to fresh media weekly at a concentration of 1
× 105 to 5 × 105 cells/mL.
Hexosaminidase assay. Mast cells were incubated
overnight at 37°C with monoclonal murine anti-DNP
IgE (clone SPE-7; Sigma Chemical Co., St. Louis, Mis-
souri, USA) at a concentration of 100 ng/mL per million
cells to give 100% occupancy of IgE receptors. Cells were
washed twice with a glucose-saline, Pipes-buffered
medium containing 1 mM calcium (Siraganian buffer;
also with KCl, MgCl2, BSA [pH 7.2]) and transferred to
96-well microtiter plates at a concentration of 500,000
cells per 75 µL. Cells were incubated with or without
adenosine for 1 minute before stimulation with antigen
(DNP-albumin, 10 ng/mL; Sigma Chemical Co.). Reac-
tions were terminated after 20 minutes by centrifuging
samples at 4°C at 2,000 g for 5 minutes. Hexosa-
minidase secretion was determined by incubating
supernatant and cell lysate with 1 mM p-nitrophenyl-N-
acetyl-β-D-glucosaminide (p-NAG, molecular weight
342.3; Sigma Chemical Co.). After a 1-hour incubation
at 37°C, 0.1 M Na2CO3/NaHCO3 was added and
absorbance was read at 405 nm. Hexosaminidase release
was expressed as a percentage of the total amount of
hexosaminidase present in the cells.
Intradermal adenosine and inosine. Mice were injected
with 100 µL of 1% Evans blue (Sigma Chemical Co.) in
PBS intravenously by tail vein. One hour later, they
were anesthetized and given 20 µL of adenosine (10–3
–10–4 M) or inosine (10–4 M) and 20 µL of PBS into the
right and left ears, respectively. One hour after intra-
dermal injections, mice were sacrificed by cervical dis-
location, and 7-mm ear punches were obtained from
each ear. The Evans blue dye was extracted by incuba-
tion in 0.5 mL of formamide at 55°C for 48 hours and
was quantitated by measuring the absorbance of Evans
blue at 610 nm with a spectrophotometer (35).
Histological analysis. Organs were harvested from
A3AR+/+ and A3AR–/– mice and fixed in 10% formalin.
Tissue was embedded in paraffin, and 5-µm sections
were cut and stained with toluidine blue. Mast-cell
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numbers in each tissue were quantitated in a blinded
fashion by counting the number of positively staining
cells in each tissue from 3 animals of each genotype.
Passive cutaneous anaphylaxis. Passive cutaneous ana-
phylaxis was performed as described previously (36).
Briefly, animals were lightly anesthetized and injected
intradermally in the right ear with 20 ng of murine mon-
oclonal anti-DNP IgE diluted in 20 µL of PBS. The left
ear was injected with PBS alone. Twenty-four hours later,
the animals were injected intravenously with 100 µg of
DNP-albumin in 100 µL of 0.9% PBS; 1% Evans blue dye
was added to permit visual localization of increased vas-
cular permeability. The reaction was quantitated at 90
minutes after injection as already described here.
Passive systemic anaphylaxis. Passive systemic anaphy-
laxis was performed as described previously (37). Briefly,
animals were injected intravenously with 200 µL of PBS
containing 20 µg of a murine monoclonal anti-DNP
IgE, and 24 hours later, with 200 µL of PBS containing
1% Evans blue dye and 1 mg DNP-albumin. Control
animals received antigen only or IgE only. Baseline tem-
perature was established for each animal using a rectal
probe before injection of the antigen. Temperature
drops due to anaphylactic response were recorded at 20,
30, 40, and 50 minutes after the injection of antigen. Ear
edema was quantitated as already described here.
Statistical analysis. Data are presented as mean ± SEM.
Statistical significance was assessed by using the
unpaired Student’s t test.
Results
Effect of adenosine and inosine on degranulation of BMMCs.
To compare the effect of adenosine and its metabolite
inosine on mast-cell function, in particular mast-cell
degranulation, BMMCs were prepared from wild-type
and A3AR–/– mice. Wild-type and A3AR–/– BMMCs were
exposed to increasing concentrations of either adeno-
sine or inosine, and degranulation was assessed by
measuring the release of hexosaminidase, an enzyme
present in mast-cell granules. No increase in hex-
osaminidase was seen upon exposure of up to 100 µM
adenosine or inosine, indicating that neither nucleoside
alone provoked degranulation of BMMCs. To compare
the ability of these 2 agents to potentiate antigen-medi-
ated BMMC degranulation, mast cells were loaded with
IgE and subsequently exposed to antigen and various
concentrations of adenosine and inosine. IgE-depend-
ent degranulation without adenosine or inosine was
similar between genotypes (27 ± 3% vs. 27 ± 5%). As
shown in Figure 1, adenosine and inosine both
enhanced antigen-mediated degranulation of wild-type
mast cells. However, a maximum increase in potentia-
tion of this response by adenosine was seen at concen-
trations approximately 10-fold lower than that seen
with inosine. At a dose of 100 µM, inosine increased
hexosaminidase release by 34 ± 4% (P = 0.008), whereas
adenosine enhanced release by 67.3 ± 11% (P = 0.028). To
determine whether inosine mediates its action through
one of the adenosine receptors, we examined the ability
of inosine to potentiate degranulation of A3AR–/– mast
cells. Similar to adenosine, inosine failed to potentiate
antigen-induced degranulation in BMMCs from
A3AR–/– mice (Figure 1). Antigen-induced degranulation
in A3AR–/– cells could, however, be potentiated by other
secretagogues such as PGE2 to similar extents as that
seen in BMMCs from wild-type animals (26 ± 6% release
with antigen; 53 ± 2% release with antigen and PGE2).
These results indicate that the ability of both adenosine
and inosine to enhance antigen-induced degranulation
of murine BMMCs occurs exclusively through activa-
tion of the A3 adenosine receptor.
Changes in vascular permeability in response to adenosine
and inosine in A3AR+/+ and A3AR–/– mice. We examined the
effects of adenosine and inosine on microvascular per-
meability and plasma protein extravasation in the skin
by intradermally injecting these nucleosides into the
pinna of the mouse ear. Evans blue dye binds to serum
proteins and remains confined to the intravascular
space unless vascular permeability is altered. Quantita-
tion of the dye present in the ear can therefore be used
to quantify the levels of plasma protein extravasation
into tissue. As shown in Figure 2a, intradermal adeno-
sine caused significant extravasation of plasma proteins
into the ears of A3AR+/+ mice. Inosine was also effective
at producing protein extravasation. However, in con-
trast to our in vitro data, inosine was at least as effective
as adenosine in producing this response. To determine
whether these effects were mediated through a specific
receptor, we measured the ability of these agents to
cause plasma protein extravasation in A3AR–/– mice. Nei-
ther adenosine nor inosine evoked dye extravasation in
any of the A3AR–/– animals tested, even at concentra-
tions as high as 1 mM (Figure 2a).
Adenosine-induced edema in mast cell–deficient mice. To
determine whether the plasma protein extravasation in
response to adenosine was due to direct effects on the
endothelium or secondary to mast cell–mediator
release, adenosine was delivered intradermally into the
pinna of the ears of mast cell–deficient mice and their
wild-type littermate controls. Although edema forma-
tion was seen in the wild-type animals, it was not
observed in the mast cell–deficient mice (Figure 2b).
These findings suggest that A3AR activation of mast
cells is the physiological mechanism behind adenosine-
induced changes in vascular permeability.
Mast-cell histology. To verify that the absence of the A3
receptor did not affect mast-cell development, mast cells
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Table 1
Number of mast cells per square millimeter 
Organ A3AR+/+ A3AR–/–
Ear 106.8 ± 4.0 102.2 ± 8.6
Skin 11.2 ± 3.3 11.2 ± 1.4
Tongue 8.0 ± 0.1 8.2 ± 0.7
Trachea 5.4 ± 0.4 4.3 ± 1.2
Stomach 5.0 ± 0.6 4.4 ± 0.4
were examined from A3AR–/– animals and controls. Mor-
phologically, BMMCs isolated from A3AR–/– mice were
indistinguishable from those obtained from A3AR+/+
animals. Tissue mast cells stained with toluidine blue
also appeared morphologically similar between geno-
types. Table 1 summarizes the number of resident mast
cells present in various tissues from A3AR–/– and A3AR+/+
mice. No differences in cell numbers were found
between genotypes in any of the tissues examined.
Quantification of mast cells in the stomach was based
on counting mast cells in the submucosa and muscu-
laris propria and did not include mucosal mast cells.
Passive cutaneous and systemic anaphylaxis. Previous
work has demonstrated that increases in plasma pro-
tein extravasation seen during a passive anaphylaxis
response in the mouse results from activation of mast
cells by antigen and IgE via the FcεR1 receptor (37).
Therefore, to determine whether tissue mast cells of
the A3AR–/– animals could respond to other stimuli
and whether the magnitude of this response was
altered as a result of loss of the A3AR, we examined
plasma protein extravasation after the induction of
passive cutaneous and systemic anaphylaxis. The
cutaneous anaphylactic response was elicited by load-
ing mast cells intradermally with murine monoclon-
al IgE specific for DNP-albumin. Twenty-four hours
later, the antigen was administered intravenously.
Similar to A3AR+/+ mice, intravenously administered
antigen led to localized plasma protein extravasation
at the site of intradermal IgE administration in
A3AR–/– animals (data not shown). While many of the
A3AR–/– mice displayed a slightly blunted response,
the observed differences between genotypes were not
statistically significant (P = 0.21).
A systemic anaphylactic response was elicited in wild-
type and A3AR–/– mice by intravenously loading tissue
mast cells with monoclonal IgE specific for DNP-albu-
min. Twenty-four hours later, the DNP antigen was
administered intravenously. In wild-type mice, passive
systemic anaphylaxis is characterized by profound
shock with hypotension, hypothermia, and increased
vascular permeability leading to generalized fluid
extravasation. We quantified the anaphylactic response
in 2 ways. First, temperature change was monitored rec-
tally at various times after administration of antigen;
and second, changes in vascular permeability were
determined by measuring Evans blue dye extravasation
into ear tissue. Antigen administration resulted in pro-
gressive hypothermia in both wild-type and A3AR–/– ani-
mals over the time interval measured (data not shown).
The body temperature dropped significantly in the ani-
mals that received IgE and antigen compared with con-
trol animals treated with either IgE alone or antigen
alone (P < 0.05). No significant differences were detect-
ed between genotypes at any time point measured. Vas-
cular permeability also increased in both wild-type and
A3AR–/– animals after antigen challenge (data not
shown). Again, no significant differences were observed
between genotypes (P = 0.31).
Adenosine-mediated edema formation in FcεR1-deficient
mice. It is possible that the ability of adenosine to initi-
ate degranulation of tissue mast cells, but not BMMCs,
is dependent on occupancy, in vivo, of the high-affinity
IgE receptor, FcεR1, with subthreshold levels of IgE and
antigen. To test this hypothesis, the response of mice
lacking the β chain of the FcεR1 receptor to adenosine
was examined. It has been shown previously that expres-
sion of functional FcεR1 in murine mast cells is depend-
ent on the expression of the β chain (33). As shown in
Figure 2b, a similar degree of plasma protein extravasa-
tion was seen in wild-type and FcεR1-deficient animals
in response to adenosine (P = 0.84). These results sug-
gest that mast-cell activation by adenosine in vivo
occurs independent of any FcεR1 receptor–mediated
signal transduction.
Discussion
Adenosine and inosine can have dramatic effects on
vascular permeability, with edema formation occurring
rapidly upon cutaneous exposure to these nucleosides.
We show here that these physiological changes are
mediated through the binding of adenosine and ino-
sine to the A3 adenosine receptor. Lack of plasma pro-
tein extravasation after the intradermal administration
of adenosine in mast cell–deficient mice fails to sup-
port a model in which adenosine induces changes in
vascular permeability by acting directly on adenosine
receptors expressed by endothelial cells. Rather, these
findings are consistent with the hypothesis that adeno-
sine and inosine mediate changes in vascular perme-
ability indirectly by activation of tissue mast cells,
which in turn release secondary mediators that act on
endothelial cells. The experiments described here also
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Figure 1
Potentiation of antigen-induced degranulation of BMMCs from
A3AR–/– and A3AR+/+ mice by adenosine and inosine. IgE-loaded mast
cells were incubated with antigen (DNP-albumin) in the presence or
absence of increasing concentrations of adenosine or inosine. The
amount of degranulation was determined by measuring the percent
hexosaminidase released from cells. Data represent the mean percent
increase in hexosaminidase release with adenosine and inosine, ±
SEM from 3 experiments, each performed in duplicate. Ado = adeno-
sine, Ino = inosine. *P < 0.03.
show that adenosine and inosine alone can provide,
through activation of the A3 receptor, sufficient signal
for degranulation of intradermal mast cells in vivo.
These findings contrast with in vitro studies using
BMMCs, in which exposure to adenosine or inosine
alone does not result in mast-cell degranulation.
Previous work has shown that adenosine can influ-
ence vascular permeability in multiple tissues, and our
results showing edema formation in the mouse after
the intradermal injection of adenosine are consistent
with these studies (9–11, 17). It has previously been dif-
ficult to definitively assign a specific adenosine recep-
tor to a given physiological response owing to the
incomplete selectivity of adenosine receptor agonists
and antagonists. Our studies show that plasma protein
extravasation in response to adenosine is mediated
entirely through activation of the A3 receptor, as adeno-
sine cannot provoke this physiological response in mice
lacking this receptor. These findings are consistent
with reports showing that pharmacologic reagents that
preferentially bind to the A3 receptor are effective at
inducing edema formation (30, 38).
To determine whether adenosine-mediated increases
in cutaneous vasopermeability are due to direct effects
on the vasculature or occur indirectly through mast
cell–mediator release, we used mast cell–deficient mice
and their congenic littermate controls. Control mice
showed the expected increase in vascular permeability
in response to adenosine, whereas mast cell–deficient
mice showed no response. These results suggest that
mast cells are required for the induction of plasma pro-
tein extravasation by adenosine and that adenosine
does not act directly on the vasculature to produce
these physiological changes. Earlier in vitro studies
using microvascular endothelial cells have shown
adenosine to have direct effects on permeability (17). It
is possible that these discrepancies reflect a difference
in the site and cell type exposed to adenosine. In the
experiments described here, adenosine was delivered to
the interstitial space. It is possible that high levels of
adenosine delivered to the luminal surface of the
endothelial cell may directly alter postcapillary perme-
ability. In vivo studies have also suggested that adeno-
sine may have direct effects on the vasculature; howev-
er, the results of most of these studies are confounded
by the presence of perivascular mast cells (9, 10).
Recently, studies of vascular permeability in the skin of
conscious rats after exposure to adenosine analogues
have suggested an indirect action through mediator
release from mast cells, as plasma protein extravasation
after the intradermal administration of an adenosine
analogue was nearly eliminated when animals were pre-
treated with either a histamine and serotonin antago-
nist or compound 48/80 that depletes mast-cell medi-
ators (30). Our results are in agreement with these
observations and provide evidence that adenosine’s
effects on cutaneous vascular permeability are mast-cell
mediated. Formal proof that these effects are indeed
mast-cell mediated awaits successful and unsuccessful
restoration of the response to adenosine in mast
cell–deficient mice reconstituted with A3AR+/+ and
A3AR–/– BMMCs, respectively.
Given our findings that the edema response to
adenosine is mast cell–dependent, and that this
response is absent in the A3AR-deficient mice, 2 possi-
ble explanations need to be considered. One possibili-
ty is that the failure to see a response in the A3AR-defi-
cient mice is due to the nonresponsiveness of mast cell
to adenosine because of the absence of A3AR receptor
expression. An alternative hypothesis is that the A3AR
plays an important role in the development, migration,
or overall survival of mast cells and that loss of this
receptor renders mice mast-cell deficient. Two lines of
experimental data support the former hypothesis. First,
mast cells were found in approximately normal num-
bers in all tissues examined and could not be distin-
guished from wild-type controls based on morpholog-
ical criteria. Perhaps more convincing data supporting
the normal development of mast cells in A3AR–/– mice
are the demonstration that loss of this receptor has
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Figure 2
Plasma protein extravasation after intradermal adenosine and ino-
sine in wild-type (+/+), A3AR-deficient (A3AR–/–), mast cell–deficient
(W/WV), and FcεR1 β-chain–deficient mice (FcεR1–/–). Mice were
injected intravenously with 100 µL of 1% Evans blue in PBS. One
hour later, 20 µL of adenosine 10–3 M or inosine 10–4 M (a), or
adenosine 10–4 M (b), was injected intradermally into the right ear
of each animal. Control ears (left ears) were injected with 20 µL of
PBS. One hour after intradermal injections, 7-mm ear biopsies were
obtained and placed in formamide at 57°C for 48 hours to extract
dye. Plasma protein extravasation was quantitated by measuring
OD at 610 nm. Data represent the mean difference in OD between
PBS-treated ears and nucleoside-treated ears, ± SEM. n = number
of animals in each group. *P < 0.005.
only a minimal impact on systemic and cutaneous IgE-
mediated anaphylaxis in these animals. A small
decrease in response to cutaneous anaphylaxis was
observed, but this difference did not reach statistical
significance. It is possible that this trend may be relat-
ed to the in vitro demonstration that adenosine, acting
through the A3 receptor, potentiates IgE-mediated
mast-cell degranulation. The role of adenosine in this
response may be difficult to measure when mast cells
are maximally stimulated in passive anaphylaxis, and
further studies with suboptimal doses of antigen or
antibody may reveal a greater role for adenosine in
these mast cell–mediated inflammatory responses.
Moreover, further insight into the contribution of
adenosine to disease processes such as asthma, in
which mast-cell activation is believed to play a role, may
be gained by examining A3AR-deficient mice in estab-
lished models of this disease.
Previous investigations using murine BMMCs have
shown adenosine’s potentiation of degranulation in
these cells to be partially pertussis-toxin sensitive (39).
These same investigators also showed that adenosine-
mediated rises in inositol trisphosphate (IP3) and intra-
cellular calcium were pertussis-toxin insensitive (39).
Because A3-mediated signal transduction has been
shown to be sensitive to pertussis toxin (40, 41), it has
been speculated that another adenosine receptor, such
as the A2B receptor, plays a role in adenosine’s actions
on BMMC degranulation. Our results showing the
potentiation of antigen-stimulated BMMC degranula-
tion by adenosine through the A3 receptor do not sup-
port these observations. A3 receptors have been shown
to interact with multiple G proteins including Gi and
Gq, and it has been suggested that A3AR stimulation of
phospholipase C may have a pertussin toxin–insensi-
tive component in some systems (42).
While adenosine can potentiate antigen-induced
mast-cell degranulation in vitro, it cannot initiate
degranulation independent of an additional stimulus.
In contrast, adenosine alone appears to be sufficient
to activate mast cells in vivo. Studies carried out in sev-
eral species support this observation (23, 24, 29–31).
Several different hypotheses can explain the profound
effect of adenosine on mast-cell function in vivo. First,
BMMCs in tissue culture may be immature and lack
the necessary signaling mechanisms required to initi-
ate degranulation in response to adenosine. Second,
the ability of adenosine to initiate degranulation may
vary between different mast-cell types. Tissue mast
cells can be classified into either connective tissue or
mucosal mast cells based on certain morphological
and histochemical characteristics, and it has been sug-
gested that BMMCs more closely resemble the latter
(21). The in vivo studies described here examine the
cutaneous response to adenosine and, therefore,
reflect activation of A3AR on connective tissue mast
cells. Finally, in vivo, low levels of antigen may be
bound to IgE receptors occupied by circulating IgE,
providing the additional signaling necessary for acti-
vation of mast cells by adenosine. The availability of
mouse lines lacking a functional FcεR1 receptor has
enabled us to test this hypothesis directly. Intradermal
administration of adenosine to these mice results in a
similar degree of plasma protein extravasation as
observed in wild-type controls, establishing that
adenosine-induced mast-cell degranulation in vivo
occurs independently of the presence of signal trans-
duction by the high affinity IgE receptor.
Although it is well accepted that adenosine is a
paracrine and autocrine mediator in a broad spectrum
of physiological responses, less information is available
concerning the functions of inosine, a primary metabo-
lite of adenosine. Two different routes for metabolism
of adenosine have been described. First, adenosine can
be used as a substrate for nucleotide synthesis produc-
ing ADP and ATP, which themselves have potent recep-
tor-mediated biologic reactions (43). Alternatively,
adenosine can be converted by adenosine deaminase to
inosine. The activity of these 2 pathways is believed to
be regulated, at least in part, by the substrate availabili-
ty (44). When levels of adenosine are low, most adeno-
sine is converted to AMP by adenosine kinase. However,
when adenosine levels increase as a result of trauma,
shock, exercise, hypoxia, or endotoxin, adenosine deam-
ination predominates, leading to significant increases
in inosine production and resultant interstitial levels of
inosine that can rise to greater than 1 mM (44, 45). The
biologic significance of these high tissue levels of ino-
sine has not been established, nor is it known whether
this metabolite mediates it actions solely by binding to
adenosine receptors or whether it mediates its effects
through yet undescribed inosine receptors. In vitro
studies have shown that inosine can potentiate antigen-
induced degranulation of both rat serosal mast cells and
rat RBL-2H3 mastlike cells (5, 46). We show here that
inosine can also potentiate the degranulation of
BMMCs. Furthermore, this response is not seen in
A3AR-deficient mast cells, demonstrating that inosine’s
actions on BMMCs are mediated through the A3 recep-
tor. These findings are consistent with recent pharma-
cologic studies that showed inosine to preferentially
bind to recombinant rat A3 receptors (5). These studies
also suggest that adenosine is more effective than ino-
sine in mediating this response and are consistent with
earlier studies with rat mast cells that showed inosine to
be some 10 times less potent that adenosine at enhanc-
ing antigen-induced degranulation (46).
Intradermal injection of inosine was at least as effec-
tive as adenosine at eliciting an edema response. This
finding is consistent with pharmacologic studies that
suggested that inosine can activate the A3 receptor (5).
Thus, the studies reported here support a physiological
role for inosine in the acute inflammatory response and
show that these effects of inosine are mediated solely
through an adenosine receptor, specifically the A3 recep-
tor. This does not rule out the possibility that other bio-
logic responses of inosine may be mediated by other
adenosine receptors or yet uncharacterized receptors.
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In summary, we have shown that both adenosine and
its principal metabolite inosine promote plasma protein
extravasation through activation of A3 adenosine recep-
tors. Lack of any changes in vascular permeability in mast
cell–deficient mice after exposure to adenosine suggests
that adenosine acts indirectly through A3 receptors on
mast cells to produce these physiological changes. These
actions of adenosine in vivo occur independently of the
presence of the expression of the high-affinity IgE recep-
tor, suggesting a more profound role for adenosine as a
modifier of the inflammatory response.
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